接受诺氟沙星预防治疗的癌症患者粪便菌群中耐氟喹诺酮大肠杆菌的出现。
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
作者信息
Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez M A, Gudiol F
机构信息
Services of Infectious Diseases, University of Barcelona, Spain.
出版信息
Antimicrob Agents Chemother. 1996 Feb;40(2):503-5. doi: 10.1128/AAC.40.2.503.
Abstract
We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.
摘要
我们研究了从25例接受预防性诺氟沙星治疗的血液系统恶性肿瘤患者中收集的122份粪便样本。在入院时以及预防治疗期间每周两次采集粪便样本。从10例（40%）患者的粪便中分离出耐氟喹诺酮的大肠杆菌菌株；2例患者在开始诺氟沙星治疗前就有耐氟喹诺酮的大肠杆菌菌株，另外8例患者的菌株随后出现。1例患者在使用诺氟沙星10天后发生了耐氟喹诺酮的大肠杆菌菌血症。
相似文献
1
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
Antimicrob Agents Chemother. 1996 Feb;40(2):503-5. doi: 10.1128/AAC.40.2.503.
2
Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.
J Hepatol. 1999 Aug;31(2):277-83. doi: 10.1016/s0168-8278(99)80225-6.
3
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.
J Antimicrob Chemother. 1999 Jul;44(1):117-20. doi: 10.1093/jac/44.1.117.
4
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.
Infection. 1998 Nov-Dec;26(6):379-84. doi: 10.1007/BF02770840.
5
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Hepatology. 1999 Apr;29(4):1064-9. doi: 10.1002/hep.510290406.
6
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Acta Haematol. 1998;99(4):206-11. doi: 10.1159/000040840.
7
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):111-8. doi: 10.1007/s10096-005-1278-x.
8
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Clin Infect Dis. 1995 Mar;20(3):557-60; discussion 561-3. doi: 10.1093/clinids/20.3.557.
9
[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
Med Clin (Barc). 1999 Sep 11;113(7):241-5.
10
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Antimicrob Agents Chemother. 1989 Aug;33(8):1318-25. doi: 10.1128/AAC.33.8.1318.
引用本文的文献
1
Prophylactic fluoroquinolones in hematopoietic stem cell transplant recipients: A meta-analytic comparison of ciprofloxacin and levofloxacin.
Medicine (Baltimore). 2025 May 9;104(19):e42317. doi: 10.1097/MD.0000000000042317.
2
Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.
Infect Drug Resist. 2017 Jun 27;10:193-199. doi: 10.2147/IDR.S133333. eCollection 2017.
3
Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem.
World J Urol. 2017 Nov;35(11):1681-1688. doi: 10.1007/s00345-017-2043-3. Epub 2017 May 3.
4
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Haematologica. 2016 Oct;101(10):1208-1215. doi: 10.3324/haematol.2016.147934. Epub 2016 Jul 28.
5
Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.
PLoS One. 2014 Jan 22;9(1):e85210. doi: 10.1371/journal.pone.0085210. eCollection 2014.
6
Defining relatedness in studies of transmission of antimicrobial-resistant organisms: variability in definitions across studies and impact of different approaches on study conclusions.
Infect Control Hosp Epidemiol. 2013 Jan;34(1):40-8. doi: 10.1086/668780. Epub 2012 Nov 21.
7
Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy.
J Clin Microbiol. 2011 Mar;49(3):1116-8. doi: 10.1128/JCM.01885-10. Epub 2010 Dec 22.
8
Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):355-60. doi: 10.1007/s10096-010-1093-x. Epub 2010 Oct 30.
9
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.
J Infect Dis. 2009 Aug 1;200(3):390-8. doi: 10.1086/600122.
10
Assessment of the use of urine samples to detect colonization with fluoroquinolone-susceptible and fluoroquinolone-resistant Escherichia coli.
Infect Control Hosp Epidemiol. 2009 Apr;30(4):396-7. doi: 10.1086/596044.
本文引用的文献
1
Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.
Antimicrob Agents Chemother. 1993 Mar;37(3):474-82. doi: 10.1128/AAC.37.3.474.
2
Antibacterial chemoprophylaxis in neutropenic patients--where do we go from here?
Clin Infect Dis. 1993 Sep;17(3):333-7. doi: 10.1093/clinids/17.3.333.
3
Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study.
Clin Infect Dis. 1993 Sep;17(3):323-32. doi: 10.1093/clinids/17.3.323.
4
Infection prevention in severely myelosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora.
Am J Med. 1994 Apr;96(4):335-41. doi: 10.1016/0002-9343(94)90063-9.
5
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.
N Engl J Med. 1994 Apr 28;330(17):1240-1. doi: 10.1056/NEJM199404283301717.
6
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
Antimicrob Agents Chemother. 1994 Apr;38(4):681-7. doi: 10.1128/AAC.38.4.681.
7
Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing.
J Clin Microbiol. 1994 Dec;32(12):3013-7. doi: 10.1128/jcm.32.12.3013-3017.1994.
8
Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.
J Clin Oncol. 1995 Jan;13(1):239-50. doi: 10.1200/JCO.1995.13.1.239.
9
Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones.
Clin Infect Dis. 1995 Apr;20(4):907-12. doi: 10.1093/clinids/20.4.907.
10
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Clin Infect Dis. 1995 Mar;20(3):557-60; discussion 561-3. doi: 10.1093/clinids/20.3.557.
Zotero 插件